FDA warning letters
A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.
7 letters match. Newest first.
-
BiologicsStephen J. Fallon, Ph.D.
FDA warns clinical investigator Stephen J. Fallon, Ph.D. over consent and record failures in an HIV self-test study.
High risk -
DrugsPratik Doshi, M.D. / Alembic Pharmaceuticals Ltd.
FDA warned investigator Dr. Pratik Doshi at Alembic's Vadodara site that a bioequivalence study consent form wrongly said nothing was experimental.
High risk -
BiologicsAdnan Dahdul, MD
FDA warns clinical investigator Dr. Adnan Dahdul over consent, eligibility and record failures in a biologics study.
High risk -
DrugsSourav K. Mishra, M.D. / All India Institute of Medical Sciences
FDA warned clinical investigator Dr. Sourav K. Mishra at AIIMS Bhubaneswar over a doxorubicin liposome bioequivalence study that broke protocol and consent rules.
High risk -
DrugsMukesh B. Chandre, M.D., MBBS/Ashirwad Hospital & Research Centre
FDA warned clinical investigator Dr. Mukesh Chandre over informed consent failures in a doxorubicin liposome bioequivalence study.
High risk -
DevicesExThera Medical Corporation
ExThera shipped Seraph 100 blood filters for compassionate use without FDA approval and promoted them as approved.
High risk -
DrugsMark S. Dacey, M.D.
FDA warns Dr. Mark S. Dacey that a trial subject underwent an optional eye-fluid sampling procedure after twice declining consent.
High risk